References
- Cunha BA. The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship. Infect Dis (Lond). 2016;48:328–329.
- Ventola CL. The drug shortage crisis in the United States: causes, impact, and management strategies. P T. 2011;36:740–757.
- ASHP Expert Panel on Drug Product Shortages, Fox ER, Birt A, James KB, et al. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009;66:1399–1406.
- Polk RE, Fox C, Mahoney A, et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44:664–670.
- Gray A, Manasse HR Jr. Shortages of medicines: a complex global challenge. Bull World Health Organ. 2012;90:158–158A.
- Alsheikh M, Seoane-Vazquez E, Rittenhouse B, et al. A comparison of drug shortages in the hospital setting in the United States and Saudi Arabia: an exploratory analysis. Hosp Pharm. 2016;51:370–375.
- Yang C, Wu L, Cai W, et al. Current situation, determinants, and solutions to drug shortages in Shaanxi Province, China: a qualitative study. PLoS One. 2016;11:e0165183.
- Barber KE, Bell AM, Travis King S, et al. Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs. Braz J Infect Dis. 2016;20:631–634.
- Hsueh K, Reyes M, Krekel T, et al. Effective antibiotic conservation by emergency antimicrobial stewardship during a drug shortage. Infect Control Hosp Epidemiol. 2017;38:356–359.